RU2013144579A - Ингибиторы киназы mst1 и способы их применения - Google Patents
Ингибиторы киназы mst1 и способы их применения Download PDFInfo
- Publication number
- RU2013144579A RU2013144579A RU2013144579/04A RU2013144579A RU2013144579A RU 2013144579 A RU2013144579 A RU 2013144579A RU 2013144579/04 A RU2013144579/04 A RU 2013144579/04A RU 2013144579 A RU2013144579 A RU 2013144579A RU 2013144579 A RU2013144579 A RU 2013144579A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- formula
- independently
- syndrome
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Соединение формулы:или его фармацевтически приемлемая соль, где:A представляет собой арил или 4-7-членный гетероцикл;X представляет собой N или CH;каждый Yи Yнезависимо представляет собой S, N или CH, при условии, что по меньшей мере один из Yи Yпредставляет собой N или CH;каждый Rнезависимо представляет собой R, -(R)SOR, -(R)SON(R), -(R)NRSOR, -(R)C(O)N(R)или -(R)NRC(O)R, или необязательно замещенный Cгидрокарбил или 2-12-членный гетерокарбил, при этом необязательное замещение производится одним или более R;каждый Rнезависимо является амино, алкоксилом, карбоксилом, циано, галогеном или гидроксилом;каждый Rнезависимо является Cгидрокарбилом, необязательно замещенным один или более из амино, алкоксила, карбоксила, циано, галогена или гидроксила;каждый Rнезависимо является водородом или необязательно замещенным Cгидрокарбилом или 2-12-членным гетерокарбилом, при этом необязательное замещение производится одним или более из амино, алкоксила, карбоксила, циано, галогена или гидроксила;Rи R, взятые вместе, формируют 5-7-членный гетероцикл, необязательно замещенный одним или более R, или:Rявляется водородом или Cалкилом; иRявляется водородом или необязательно замещенным Cгидрокарбилом или 2-12-членным гетерокарбилом, при этом необязательное замещение производится одним или несколькими R;каждый Rнезависимо является амино, алкоксилом, карбоксилом, циано, галогеном или гидроксилом;k представляет собой 0 или 1;m представляет собой 0-3;n представляет собой 0 или 1; иp представляет собой 0-2;при условии, что Rне является водородом, когда X является CH, Yявляется CH, Yявляется CH и Rявляется водородом.2. Соединение по п.1, где Rне является водородом.3. Соединение по п.1, которое име
Claims (26)
1. Соединение формулы:
или его фармацевтически приемлемая соль, где:
A представляет собой арил или 4-7-членный гетероцикл;
X представляет собой N или CH;
каждый Y1 и Y2 независимо представляет собой S, N или CH, при условии, что по меньшей мере один из Y1 и Y2 представляет собой N или CH;
каждый R1 независимо представляет собой R1A, -(R1B)nSOpR1C, -(R1B)nSOpN(R1C)2, -(R1B)nNR1CSOpR1C, -(R1B)nC(O)N(R1C)2 или -(R1B)nNR1CC(O)R1C, или необязательно замещенный C1-12 гидрокарбил или 2-12-членный гетерокарбил, при этом необязательное замещение производится одним или более R1A;
каждый R1A независимо является амино, алкоксилом, карбоксилом, циано, галогеном или гидроксилом;
каждый R1B независимо является C1-12 гидрокарбилом, необязательно замещенным один или более из амино, алкоксила, карбоксила, циано, галогена или гидроксила;
каждый R1C независимо является водородом или необязательно замещенным C1-12 гидрокарбилом или 2-12-членным гетерокарбилом, при этом необязательное замещение производится одним или более из амино, алкоксила, карбоксила, циано, галогена или гидроксила;
R2 и R3, взятые вместе, формируют 5-7-членный гетероцикл, необязательно замещенный одним или более R3A, или:
R2 является водородом или C1-4 алкилом; и
R3 является водородом или необязательно замещенным C1-12 гидрокарбилом или 2-12-членным гетерокарбилом, при этом необязательное замещение производится одним или несколькими R3A;
каждый R3A независимо является амино, алкоксилом, карбоксилом, циано, галогеном или гидроксилом;
k представляет собой 0 или 1;
m представляет собой 0-3;
n представляет собой 0 или 1; и
p представляет собой 0-2;
при условии, что R3 не является водородом, когда X является CH, Y1 является CH, Y2 является CH и R2 является водородом.
2. Соединение по п.1, где R2 не является водородом.
13. Соединение по любому из пп. 1-12, где X представляет собой N.
14. Соединение по любому из пп. 1-10 и 12, где Y1 представляет собой CH.
15. Соединение по любому из пп. 1-11, где Y2 представляет собой CH.
16. Соединение по любому из пп. 5-12, где Z представляет собой N.
17. Соединение по любому из пп. 5-12, где Z представляет собой CR1.
18. Соединение по любому из пп. 1-12, где R1 представляет собой (R1B)nSOpR1C, -(R1B)nSOpN(R1C)2, -(R1B)nNR1CSOpR1C, -(R1B)nC(O)N(R1C)2 или -(R1B)nNR1CC(O)R1C.
19. Соединение по п.18, где n=0.
20. Соединение по п.18, где p=2.
22. Состав, включающий соединение по любому из пп. 1-21 и фармацевтически приемлемые вспомогательные вещества или растворитель.
23. Применение соединения по любому из пп. 1-21 или состава по п.22 для ингибирования MST1.
24. Применение соединения по любому из пп. 1-21 или состава по п.22 для лечения, контроля или предотвращения воспалительного или аутоиммунного заболевания или нарушения.
25. Применение по п.24, где аутоиммунным заболеванием или нарушением является аутоиммунная ахлоргидрия, болезнь Аддисона, анкилозирующий спондилит, антифосфолипидный синдром, астма (например, бронхиальная астма), атопический дерматит, аутоиммунный атопический гастрит, болезнь Бехчета, глютеновая энтеропатия, болезнь Крона, синдром Кушинга, дерматомиозит, синдром Гудпасчера, реакция трансплантат против хозяина, болезнь Грейвса, тиреоидит Хашимото, гепатит (например, воспалительный и вызванный алкоголем), идиопатическая атрофия надпочечников, идиопатическая тромбоцитопения, синдром Кавасаки, синдром Ламберта-Итона, красная волчанка, рассеянный склероз, тяжелая миастения, пемфигоид, обыкновенная пузырчатка, пернициозная анемия, поллиноз, узелковый полиартериит, первичный биллиарный цирроз печени, первичный склерозирующий холангит, псориаз, псориатический артрит, синдром Рейно, синдром Рейтера, рецидивирующий полихондрит, ревматоидный артрит, синдром Шмидта, склеродермия, синдром Шегрена, симпатическая офтальмия, артериит Такаясу, темпоральный артериит, тиреотоксикоз, отторжение трансплантата (например, органа, клетки или костного мозга), диабет 1-го типа, язвенный колит, увеит и гранулематоз Вегенера.
26. Применение по п.25, где аутоиммунным заболеванием или нарушением является болезнь Крона, реакция трансплантат против хозяина, псориаз, ревматоидный артрит или язвенный колит.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161449171P | 2011-03-04 | 2011-03-04 | |
US61/449,171 | 2011-03-04 | ||
PCT/US2012/027376 WO2012121992A1 (en) | 2011-03-04 | 2012-03-02 | Mst1 kinase inhibitors and methods of their use |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2013144579A true RU2013144579A (ru) | 2015-04-10 |
Family
ID=45852728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013144579/04A RU2013144579A (ru) | 2011-03-04 | 2012-03-02 | Ингибиторы киназы mst1 и способы их применения |
Country Status (16)
Country | Link |
---|---|
US (2) | US8440652B2 (ru) |
EP (1) | EP2681206B1 (ru) |
JP (1) | JP5997709B2 (ru) |
KR (1) | KR20140014205A (ru) |
CN (1) | CN103429582A (ru) |
AR (1) | AR085607A1 (ru) |
AU (1) | AU2012225805B2 (ru) |
CA (1) | CA2828578A1 (ru) |
ES (1) | ES2639426T3 (ru) |
IL (1) | IL227953A0 (ru) |
MX (1) | MX2013009953A (ru) |
RU (1) | RU2013144579A (ru) |
SG (1) | SG193293A1 (ru) |
TW (1) | TW201247626A (ru) |
WO (1) | WO2012121992A1 (ru) |
ZA (1) | ZA201306188B (ru) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101745331B1 (ko) | 2008-12-19 | 2017-06-09 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 피라진 유도체 |
JP2013526538A (ja) * | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
AU2011253025A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2012013082A (es) * | 2010-05-12 | 2013-05-09 | Vertex Pharma | Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr. |
KR102184246B1 (ko) | 2011-09-30 | 2020-12-01 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 화합물의 제조 방법 |
BR112014007690B1 (pt) | 2011-09-30 | 2022-10-04 | Vertex Pharmaceuticals Incorporated | Usos de inibidores de atr no tratamento de câncer pancreático e câncer de pulmão de células não pequenas |
WO2013121387A1 (en) * | 2012-02-17 | 2013-08-22 | University Of Cape Town | Anti -malarial agents |
RS56673B1 (sr) | 2012-04-05 | 2018-03-30 | Vertex Pharma | Jedinjenja korisna kao inhibitori atr kinaze i kombinovane terapije koje ih koriste |
US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
CN103145692B (zh) * | 2013-03-12 | 2014-07-16 | 盐城工学院 | 一种4,5-二氢-6H-环戊烷并[b]噻吩-6-酮的制备方法 |
CN103232471A (zh) * | 2013-04-16 | 2013-08-07 | 盛世泰科生物医药技术(苏州)有限公司 | 一种4,5-二氢噻吩并[2,3-c]吡咯-6-酮的合成方法 |
MX355480B (es) * | 2013-11-01 | 2018-04-19 | Novartis Ag | Amino-heteroaril-benzamidas como inhibidores de cinasa. |
US10710978B2 (en) * | 2015-03-31 | 2020-07-14 | Dana-Farber Cancer Institute, Inc. | STK4 inhibitors for treatment of hematologic malignancies |
WO2016210345A1 (en) * | 2015-06-25 | 2016-12-29 | The California Institute For Biomedical Research | Composition and methods for inhibiting mammalian sterile 20-like kinase 1 |
WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
CN105859732B (zh) * | 2016-04-11 | 2018-04-06 | 浙江海正药业股份有限公司 | 制备ad‑35的工艺 |
WO2019006512A1 (en) * | 2017-07-07 | 2019-01-10 | The University Of Queensland | REGENERATION OF CARDIOMYOCYTES |
EP3655392A1 (en) | 2017-07-17 | 2020-05-27 | Abbvie Deutschland GmbH & Co. KG | 1,2,3,4-substituted quinoline compounds as s1p modulators |
US10899733B2 (en) | 2017-08-23 | 2021-01-26 | Oregon Health & Science University | Inhibitors of PARPs that catalyze mono-ADP-ribosylation |
AU2018386184B2 (en) | 2017-12-13 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Compounds for the degradation of STK4 and treatment of hematologic malignancies |
US11306079B2 (en) | 2017-12-21 | 2022-04-19 | Incyte Corporation | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors |
US20220280530A1 (en) * | 2019-08-08 | 2022-09-08 | Anhui Newstar Pharmaceutical Development Co., Ltd. | Prevention or treatment of diseases and disorders associated with tissue damage |
TW202202495A (zh) * | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物 |
CN113528425B (zh) * | 2020-04-15 | 2023-05-30 | 合肥中科普瑞昇生物医药科技有限公司 | 一种用于乳腺上皮肿瘤细胞的培养基和培养方法 |
AU2022267407A1 (en) * | 2021-04-30 | 2023-11-09 | Ontario Institute For Cancer Research (Oicr) | Substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1) |
WO2022226667A1 (en) * | 2021-04-30 | 2022-11-03 | Ontario Institute For Cancer Research (Oicr) | Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1) |
EP4330246A1 (en) * | 2021-04-30 | 2024-03-06 | Ontario Institute for Cancer Research (OICR) | Halo-substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1) |
WO2022232632A1 (en) * | 2021-04-30 | 2022-11-03 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
WO2022226668A1 (en) * | 2021-04-30 | 2022-11-03 | Ontario Institute For Cancer Research (Oicr) | Halo-substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1) |
CN115595308A (zh) * | 2021-07-08 | 2023-01-13 | 合肥中科普瑞昇生物医药科技有限公司(Cn) | 一种用于肺癌上皮细胞的培养基、培养方法及其应用 |
EP4198033A1 (en) | 2021-12-14 | 2023-06-21 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
WO2023110473A1 (en) | 2021-12-14 | 2023-06-22 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
WO2024074461A1 (en) | 2022-10-03 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Use of inhibitors of the hippo signalling pathway for the treatment of chronic nephropathies |
WO2024104441A1 (en) * | 2022-11-17 | 2024-05-23 | Insilico Medicine Ip Limited | Salt-inducible kinases (sik) inhibitors and methods of uses thereof |
CN117567266A (zh) * | 2023-11-07 | 2024-02-20 | 康龙化成手性医药技术(宁波)有限公司 | 一种制备2-甲基环丙羧酸的方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1919895A2 (en) * | 2005-08-02 | 2008-05-14 | Lexicon Pharmaceuticals, Inc. | 2-aminoaryl pyridines as protein kinases inhibitors |
CA2652816A1 (en) * | 2006-05-23 | 2007-12-06 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
CA2654358A1 (en) | 2006-06-22 | 2007-12-27 | Biovitrum Ab (Publ) | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
EP1900727A1 (en) * | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
MX2011004953A (es) | 2008-11-10 | 2011-12-14 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
DE102009033208A1 (de) * | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | Aminopyridinderivate |
ES2551875T3 (es) * | 2010-01-18 | 2015-11-24 | Mmv Medicines For Malaria Venture | Agentes nuevos contra la malaria |
-
2012
- 2012-03-02 SG SG2013066378A patent/SG193293A1/en unknown
- 2012-03-02 AU AU2012225805A patent/AU2012225805B2/en active Active
- 2012-03-02 ES ES12709439.9T patent/ES2639426T3/es active Active
- 2012-03-02 EP EP12709439.9A patent/EP2681206B1/en active Active
- 2012-03-02 KR KR1020137025752A patent/KR20140014205A/ko not_active Application Discontinuation
- 2012-03-02 MX MX2013009953A patent/MX2013009953A/es not_active Application Discontinuation
- 2012-03-02 WO PCT/US2012/027376 patent/WO2012121992A1/en active Application Filing
- 2012-03-02 CN CN2012800117495A patent/CN103429582A/zh active Pending
- 2012-03-02 RU RU2013144579/04A patent/RU2013144579A/ru not_active Application Discontinuation
- 2012-03-02 US US13/410,407 patent/US8440652B2/en active Active
- 2012-03-02 CA CA2828578A patent/CA2828578A1/en active Pending
- 2012-03-02 JP JP2013556879A patent/JP5997709B2/ja active Active
- 2012-03-02 AR ARP120100691A patent/AR085607A1/es unknown
- 2012-03-03 TW TW101107202A patent/TW201247626A/zh unknown
-
2013
- 2013-05-03 US US13/886,351 patent/US20140051681A1/en not_active Abandoned
- 2013-08-14 IL IL227953A patent/IL227953A0/en unknown
- 2013-08-16 ZA ZA2013/06188A patent/ZA201306188B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2639426T3 (es) | 2017-10-26 |
EP2681206A1 (en) | 2014-01-08 |
CN103429582A (zh) | 2013-12-04 |
ZA201306188B (en) | 2014-10-29 |
US20140051681A1 (en) | 2014-02-20 |
CA2828578A1 (en) | 2012-09-13 |
IL227953A0 (en) | 2013-09-30 |
JP2014510072A (ja) | 2014-04-24 |
AR085607A1 (es) | 2013-10-16 |
TW201247626A (en) | 2012-12-01 |
MX2013009953A (es) | 2013-09-26 |
US20120225857A1 (en) | 2012-09-06 |
SG193293A1 (en) | 2013-10-30 |
AU2012225805A1 (en) | 2013-09-05 |
JP5997709B2 (ja) | 2016-09-28 |
US8440652B2 (en) | 2013-05-14 |
KR20140014205A (ko) | 2014-02-05 |
AU2012225805B2 (en) | 2017-03-02 |
WO2012121992A1 (en) | 2012-09-13 |
EP2681206B1 (en) | 2017-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013144579A (ru) | Ингибиторы киназы mst1 и способы их применения | |
HRP20210745T1 (hr) | Supstituirani spojevi tetrahidrokinolinona kao ror gama modulatori | |
JP2016508505A5 (ru) | ||
EA201891841A1 (ru) | 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов | |
MY192109A (en) | Aminopyrimidinyl compounds as jak inhibitors | |
MX2020014098A (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington. | |
HRP20210748T1 (hr) | Postupak priprave spojeva s aktivnošću inhibitora hiv integraze | |
HRP20210291T1 (hr) | Imunoregulatorna sredstva | |
RU2013158933A (ru) | Новые модуляторы иммунной системы родственные заявки | |
JP2014505032A5 (ru) | ||
RU2014102956A (ru) | Ингибиторы т-клеточной активации | |
TW201612354A (en) | Group 6 film forming compositions for vapor deposition of group 6 transition metal-containing films | |
JO3430B1 (ar) | مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
MX2016006336A (es) | Compuestos pirazolopirimidina. | |
JP2015506985A5 (ru) | ||
JP2019529444A5 (ru) | ||
EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
JP2011508756A5 (ru) | ||
JP2009513718A5 (ru) | ||
RU2015137757A (ru) | Производные пиридазинон-амидов | |
RS53244B (en) | 1`-SUBSTITUTED-CARB-NUCLEOSIDE PROTECTION FOR ANTI-VIRUS TREATMENT | |
RU2016151390A (ru) | Ингибиторы мтн1 для лечения воспалительных и аутоиммунных заболеваний | |
JO3811B1 (ar) | مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv | |
JP2017510660A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150303 |